BioSpace News Archive

CEO of Biostrap, a digital health company, goes public with his personal data showing the decline of his health after contracting SARS-CoV-2 and becoming symptomatic with COVID-19.

Ohio-based company continues to help international communities plan COVID-19 Vaccine distribution plans by sharing learned experiences with the likes of Walgreens, Puerto Rico National Guard, University of North Carolina and others, providing flexibility as vaccine requirements adjust.

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease, today announced a positive opinion has been adopted from the Paediatric Committee (PDCO) of the European Medicines Agency (EMA

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced the launch of its Linea™ COVID-19 Selective Genomic Surveillance™ (SGS) Mutation Panel (the “SGS Panel”) to enhance the utility of limited Next Generation Sequencing

FRR will provide a practical overview of the innovative COVID-19 Pandemic Management Platform, Fionet.

Mr. Martin has 20 years of biotechnology and pharmaceutical industry experience developing and commercializing innovative therapies in the fields of immunology, oncology and neurology.

Ermium Therapeutics SAS, a research-stage biotechnology company developing innovative therapies for auto-immune diseases is announcing today the expansion of the Company executive management team with the appointment of Dr Annegret Van der Aa as Chief Scientific Officer (CSO) and Chief Development Officer (CDO).

ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations, today announced that Mr. Brendan Brennan, CFO of ICON plc,

Battelle recently has developed a microneutralization assay, which uses live SARS-CoV-2 virus to analyze the neutralizing response against the virus in human serum samples

In addition to the acquisition of the data, Prof. Nutt has been appointed as Head of Research to lead Awakn’s next generation psychedelic molecule development programme.